North America Insulin Infusion Pumps Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The North American insulin infusion pumps market encompasses devices that deliver continuous or programmable insulin to patients with diabetes, replacing or supplementing multiple daily injections. Valued at approximately $3.35 billion in 2025, the market represents a dominant share of the global insulin delivery landscape, with North America accounting for roughly 30-40% of worldwide advanced drug and hormone delivery device channels. The U.S. alone is home to an estimated 2.07 million individuals living with type 1 diabetes, forming the core patient base for pump therapy adoption.

• •Market valued at approximately $3.35 billion in 2025 across North America
• •North America holds roughly 30-40% of the global advanced drug delivery device market
• •The United States is the single largest standalone insulin pump market worldwide

A primary catalyst for market expansion is the 2025 endorsement by the American Diabetes Association Standards of Care, which now explicitly recommends insulin pump therapy for individuals with type 2 diabetes already on multiple daily injections, vastly broadening the addressable patient population beyond the traditional type 1 diabetes cohort. Rising diabetes incidence across North America, combined with growing patient and clinician familiarity with pump-based regimens, continues to accelerate adoption. Insurance reimbursement frameworks in the U.S. also play a critical role in determining patient access to automated pump technology.

• •ADA Standards of Care (2025) now recommend pump therapy for type 2 diabetes patients on multiple daily injections
• •Approximately 2.07 million people in the U.S. are estimated to live with type 1 diabetes
• •Insurance reimbursement structures in the U.S. directly influence adoption rates for automated pump devices

The market spans two primary device categories: traditional tubed insulin pumps and tubeless patch pumps, alongside hybrid closed-loop automated systems that integrate continuous glucose monitoring to adjust insulin delivery in real time. The United States dominates regional demand, driven by favorable reimbursement policies and high healthcare spending, while Canada represents a smaller but growing secondary market. Overall, North America's outsized share of the global medical device sector, approximately 40%, underscores its structural advantage in insulin pump adoption.

• •Device categories include traditional tubed pumps, tubeless patch pumps, and hybrid closed-loop automated systems
• •The United States dominates the regional market, supported by favorable insurance reimbursement paradigms
• •North America commands roughly 40% of the global medical device market overall

What are the recent trends and outlook?

A clear and ongoing shift is underway in North America from conventional multiple daily injection therapy toward patch pumps and automated hybrid closed-loop systems, a transition documented across longitudinal U.S. adoption data. Industry investment is increasingly directed toward fully automated insulin delivery systems that minimize patient intervention, alongside miniaturized patch pump designs offering improved discretion and ease of use. With the market projected to exceed $5.3 billion by 2032 at its current growth trajectory, continued innovation in device interoperability and payer coverage expansion are expected to sustain momentum.

• •Growing shift from traditional injections toward patch pumps and hybrid closed-loop automated systems documented in U.S. adoption trends
• •Market projected to exceed $5.3 billion by 2032 at a 6.5-6.7% CAGR
• •Future growth supported by advancements in automated delivery, miniaturized patch designs, and expanding insurance coverage